Phase III, randomized trail (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). ASCO Annual Meeting, LBA 109, ASCO Daily News, Saturday May 30 2015, D12 - Paz-Ares, L